Compare Chubb Ltd (CB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Inovio Pharmaceuticals Inc — how do they compare? Chubb Ltd trades at $343.77 (market cap $133.90B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Chubb Ltd is far larger — about 1704.6× Inovio Pharmaceuticals Inc's market cap, and Chubb Ltd pays a 1.18% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CB | INO | |
|---|---|---|
Market Cap | $133.90B | $78.55M |
Sector | Financials | Health |
52-Week High | $363.50 | $2.87 |
52-Week Low | $268.20 | $0.66 |
Enterprise Value | $154.74B | $49.56M |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $345.53, down 0.8% on the day, with a neutral technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates at $7.26, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Analyst consensus is bullish with a $366.83 price target, and recent news highlights strategic partnerships and leadership appointments.
The outlook for CB is positive, supported by consistent earnings beats, robust profitability, and a favorable analyst stance. Key risks include market volatility and competitive pressures in the insurance sector. The stock presents a value opportunity with a P/E of 12.3, but investors should monitor macroeconomic factors affecting the industry.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
